Financial Performance - Net revenue for Q3 2024 was $1,278.5 million, a 17.0% increase from $1,093.0 million in Q3 2023[2] - Gross profit for Q3 2024 was $256.7 million, representing 20.1% of net revenue, compared to $254.3 million or 23.3% of net revenue in Q3 2023[2] - Net income for Q3 2024 was $53.9 million, down 4.3% from $56.3 million in Q3 2023, with diluted earnings per share remaining at $0.31[2] - Adjusted net income for Q3 2024 was $70.7 million, a decrease of 3.2% from $73.1 million in Q3 2023[2] - Adjusted EBITDA for Q3 2024 was $115.6 million, up 5.3% from $109.8 million in Q3 2023[2] - Net income for the nine months ended September 30, 2024, was $151,690,000, a decrease of 27.8% compared to $209,913,000 for the same period in 2023[14] - EBITDA for the nine months ended September 30, 2024, was $286,729,000, down 21.4% from $365,056,000 in the prior year[15] - Adjusted net income for the nine months ended September 30, 2024, was $197,329,000, an increase of 3.7% compared to $190,621,000 for the same period in 2023[15] - The company’s diluted earnings per share for the nine months ended September 30, 2024, was $0.87, down from $1.16 in the same period of 2023[15] - The company’s adjusted earnings per share for the nine months ended September 30, 2024, was $1.14, compared to $1.05 for the same period in 2023, reflecting an increase of 8.6%[15] Cash Flow and Liquidity - Cash flow from operations for Q3 2024 was $160.4 million, significantly higher than $61.0 million in Q3 2023[2] - Cash and cash equivalents at the end of Q3 2024 were $483.0 million, an increase from $343.8 million at the end of 2023[10] - Net cash provided by operating activities for the nine months ended September 30, 2024, was $287,270,000, compared to $320,326,000 in the same period of 2023, reflecting a decrease of 10.3%[14] - Cash and cash equivalents at the end of the period increased to $483,026,000 from $386,489,000, representing a growth of 25.0% year-over-year[14] Investment and Stock Activity - The company repurchased approximately $41.9 million of stock in Q3 2024[2] - The company reported a net cash used in investing activities of $25,266,000 for the nine months ended September 30, 2024, a decrease from $40,725,000 in the prior year[14] Operational Challenges - Supply chain disruptions related to intravenous solution bags are anticipated to negatively impact Q4 2024 financial results[2] - The company experienced a significant increase in accounts payable, which rose to $164,754,000 from $50,726,000, indicating a change in working capital dynamics[14] - The company’s interest expense for the nine months ended September 30, 2024, was $38,150,000, slightly down from $38,816,000 in the previous year[15] Future Outlook - The company expects full year 2024 net revenue to be between $4.9 billion and $4.95 billion[3]

Company Overview - Option Care Health Inc. is the nation's largest independent provider of home and alternate site infusion services, employing over 7,500 team members, including more than 4,500 clinicians [3] Upcoming Financial Results - The company will release its third quarter results for the period ended September 30, 2024, on October 30, 2024, before the market opens [1] - A conference call to review the results will be hosted by the management team at 8:30 a.m. E.T. on the same day [1] Conference Call Details - Participants can pre-register for the conference call via a provided link and access it through a live audio webcast [2] - A replay of the call will be available shortly after its completion and will remain accessible for approximately 90 days [2]

Investors interested in stocks from the Medical - Outpatient and Home Healthcare sector have probably already heard of Option Care (OPCH) and Astrana Health, Inc. (ASTH) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look. The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and es ...

Shares of Option Care (OPCH) have gained 10.1% over the past four weeks to close the last trading session at $29.69, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $39.13 indicates a potential upside of 31.8%. The mean estimate comprises eight short-term price targets with a standard deviation of $2.64. While the lowest estimate of $36 indicates a 21.3% increase from the curren ...

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies. Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use fundamental analysis and traditional valuation metrics to find stocks that they ...

What's Next for Option Care? Ahead of this earnings release, the estimate revisions trend for Option Care: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. This company is expected to post quar ...

BANNOCKBURN, Ill., July 31, 2024 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the "Company" or "Option Care Health") (Nasdaq: OPCH), the nation's largest independent provider of home and alternate site infusion services, announced today financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Results and Highlights Note that the second quarter of 2023 net income and cash flow from operations includes $62.8 million related to the termination payment received on behalf of A ...

BANNOCKBURN, IL., July 31, 2024 - Option Care Health, Inc. (the "Company" or "Option Care Health") (Nasdaq: OPCH), the nation's largest independent provider of home and alternate site infusion services, announced today financial results for the second quarter ended June 30, 2024. Note that the second quarter of 2023 net income and cash flow from operations includes $62.8 million related to the termination payment received on behalf of Amedisys, net of merger-related expenses and taxes. Conference Call OPTIO ...

Conference Call Details About Option Care Health For Investor Inquiries: BANNOCKBURN, Ill., July 08, 2024 (GLOBE NEWSWIRE) -- Option Care Health Inc. ("Option Care Health") (NASDAQ: OPCH), the nation's largest independent provider of home and alternate site infusion services, today announced that the company will release results for its second quarter ended June 30, 2024 on Wednesday, July 31, 2024 before the market opens. In conjunction, the management team will host a conference call to review the results ...

BANNOCKBURN, Ill., July 08, 2024 (GLOBE NEWSWIRE) -- Option Care Health Inc. ("Option Care Health") (NASDAQ: OPCH), the nation's largest independent provider of home and alternate site infusion services, today announced that the company will release results for its second quarter ended June 30, 2024 on Wednesday, July 31, 2024 before the market opens. In conjunction, the management team will host a conference call to review the results at 8:30 a.m. E.T. on the same day. Conference Call Details Participants ...